Neuphoria Therapeutics Inc.
NEUP - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.5M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $16.50 Million |
|---|---|
| Enterprise Value | $-3,326,617.00 |
| Earnings per Share | $-3.06 |
| Beta | 0.75 |
| Outstanding Shares | 5,411,334 |
Return
| Return on Equity | -54.68% |
|---|---|
| Return on Assets | -46.86% |
| Return on Invested Capital | -39.67% |
Valuation & Multiples
| P/E Ratio | -0.42 |
|---|---|
| PEG | 0.43 |
| Price to Sales | - |
| Price to Book Ratio | 0.76 |
| Enterprise Value to Revenue | -2.83 |
| Enterprise Value to EBIT | 0.3 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 18, 2026
EPS Estimate
$-0.56
Consensus analyst estimateRevenue Estimate
$996,483
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 36.85%▲ 4.36% |
|---|---|
| Total Invested | $8.71M▲ 21.78% |
| Investors Holding | 22▲ 3.00% |
About Bionomics Ltd.
1 employees
CEO: Spyridon Papapetropoulos
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals l...